Go to navigation
Go to content
???astrazeneca_global_websites_new???
AstraZeneca Worldwide
Search
Main navigation
Home
LDL-C lowering
HDL-C raising
Raising HDL-C across dose range
Triglyceride reduction
Well tolerated
Prescribed in millions of patients
Initiating CRESTOR treatment
Safety and tolerability
Prescribing information
Person behind the numbers
Clinical research
Cardiovascular disease background
Resources
References
Event & congresses
Feedback
Sitemap
CRESTOR in your country
You are here
Home
CRESTOR produces significant increase in HDL-C [1]
Epidemiology studies have shown that HDL-C levels influence cardiovascular riskalongside LDL-C levels
34
. A 1 % change in HDL-C has been shown to beassociated with a 1-3 % reduction in CHD risk
33-36
.
Page tools
Print
Bookmark this page
CRESTOR is a trademark of the AstraZeneca group of companies.
Rosuvastatin calcium is manufactured underlicensefromShionogi&CO,Ltd,Osaka, Japan